Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04865887 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
A Phase 2 study of Cervical Cancer and Metastatic Cervical Cancer, sponsored by Georgetown University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 4
- Study locations
NCT04865887: Recruiting Phase 2 study of Cervical Cancer and Metastatic Cervical Cancer, sponsored by Georgetown University.
NCT04865887 is a Phase 2 study of Cervical Cancer and Metastatic Cervical Cancer that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 35 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04865887, a Phase 2 study of Cervical Cancer and Metastatic Cervical Cancer, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Primary Outcome
To evaluate the clinical activity (as assessed by objective response rate \[ORR\]) of specific pembrolizumab-lenvatinib combination.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (4)
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
- Medstar Washington Hospital Center - Washington D.C.
Georgia
- Georgia Cancer Center at Augusta University - Augusta
New Jersey
- John Theurer Cancer Center at Hackensack UMC - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-10-07 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What NCT04865887 shows while recruiting
NCT04865887 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04865887 reports a single indexed study location in District of Columbia, Georgia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04865887 about?
NCT04865887 is a clinical study titled "Pembrolizumab and Lenvatinib in Advanced Cervical Cancer". This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (V...
What is the current status of trial NCT04865887?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-10-07. Estimated completion is 2026-07.
What conditions does trial NCT04865887 study?
This clinical trial studies the following conditions: Cervical Cancer, Metastatic Cervical Cancer.
What interventions are being tested in trial NCT04865887?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04865887?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04865887 being conducted?
This trial has 4 study locations across District of Columbia, Georgia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04865887's enrollment target sits among peer trials
35 115th of 144 higher than 30 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
RECRUITING · Phase 2
-
Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)
RECRUITING · Phase 2
-
PROton Therapy for Post Surgical Treatment of GYNecologic Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI